1999-2003  
**Title:** Health Status and Medical Treatment of the Future Elderly: Implications for Medicare Program Expenditures  
**Sponsor:** Center for Medicare and Medicaid Services  
**Amount:** $1,260,259

1999-2002  
**Title:** Cost of Cancer Treatment Study  
**Sponsor:** NIH, NCI, and NSF  
**Amount:** $3,118,310

1999-2002  
**Title:** Insurance Choices in the Medicare Population  
**Sponsor:** National Institute on Aging  
**Amount:** $648,406

1998-2002  
**Title:** Evaluation of the Medicare/DoD Subvention Demonstration  
**Sponsor:** Health Care Financing Administration  
**Amount:** $1,411,439

1998  
**Title:** Feasibility Study to Measure the Cost of Cancer Trials  
**Sponsor:** National Cancer Institute and National Science Foundation  
**Amount:** $400,000

1993-1994  
**Title:** HMO Cost Performance: A Simultaneous Equations Approach  
**Sponsor:** Agency for Health Care Policy and Research  
**Amount:** $22,000

**PUBLICATIONS**  
**Journals**


41. Jena A, Goldman D, Karaca-Mandic P. “Hospital Prescribing of Opioids to Medicare Beneficiaries.”
    JAMA Internal Medicine, 176(7):990-997, 2016.
42. Agus D, Gaudette É, Goldman D, Messali A. “The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older.”
44. Jena A, Blumenthal D, Stevens W, Chou J, Ton T, Goldman D. “Value of Improved Lipid Control in Patients at High Risk for Adverse Cardiac Events.”
46. Goldman D. “The Economic Promise of Delayed Aging.”
    Cold Spring Harbor Perspectives in Medicine, 6(5):a025072, December 18, 2015.


57. Gaudette E, Goldman D, Messali A, Sood N. “Do Statins Reduce the Health and Health Care Costs of Obesity?”


JAMA Internal Medicine, 175(7):1171-9, 2015.


JAMA Internal Medicine, 175(4):617-23, 2015.


66. Jena A, Prasad V, Goldman D, Romley J. “Mortality and Treatment Patterns Among Patients Hospitalized With Acute Cardiovascular Conditions During Dates of National Cardiology Meetings.”
JAMA Internal Medicine, 175(2):237-44, 2015.


69. Stevens W, Philipson T, Khan Z, MacEwan J, Linthicum M, Goldman D. “Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007.”


87. Sood N, Juday T, Vanderpuye-Orgle J, Rosenblatt L, Romley JA, Peneva D, Goldman D. “HIV Care Providers Emphasize The Importance Of The Ryan White Program For Access To And Quality Of Care.” 


91. Lowsky J, Olshansky SJ, Bhattacharya J, Goldman D. “Heterogeneity in Healthy Aging.” 


*American Journal of Managed Care*, 10(Special Issue 2):SP70-76, 2013.


100. Philipson T, Snider J, Lakdawalla D, Stryckman B, Goldman D. “Impact of Oral Nutritional Supplementation on Hospital Outcomes.”


Goldman\12


†Awarded the Eugene Garfield Economic Impact Prize.


197. Goldman D, Bao Y. “Effective HIV Treatment and the Employment of HIV+ Adults.”


199. Lakdawalla D, Bhattacharya J, Goldman D. “Are the Young Becoming More Disabled?”


206. Goldman D and Zissimopouloos JM. "High out-of-Pocket Health Care Spending by the Elderly."  

207. Bhattacharya J, Goldman D, Lakdawalla D. “Counterpoint: A Response to the Editorials by Manton and Williamson,”  

208. Goldman D. “Evaluating the Total Costs of Cancer” [commentary].


212. Lewis J, Kilgore M, Goldman D, et al. "The Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials."


216. Goldman D, Smith J. “Can Patient Self-Management Help Explain the SES Health Gradient?”

Topics in Economic Analysis and Policy, 2(1), 2002


222. Goldman D. “Costs of Conducting Cancer Clinical Trials.”

Medical Care Research and Review, 58(1):31-59, 2001


‡Awarded the NIHCM Excellence in Research Prize.


Books
Book Chapters and Reports


EDITORIALS


260. Goldman D. “Here’s how we can control drug costs while spurring innovation.”
262. Trish E, Goldman D. “Ending drug rebates will increase Medicare Part D premiums. Most seniors will be insulated from it.”
    *STAT*, February 21, 2019.
263. Chou J, Huber C, Goldman D. “Double Jeopardy In Health—It’s Time For Employers To Care.”
264. Goldman D, Green R. “California needs public infrastructure, but not a bullet train.”
    *Sacramento Bee*, October 11, 2018.
265. Goldman D. “When we find a cure, price it like Netflix to ensure access.”
266. Mattke S, Lakdawalla D, Goldman D. “The Long Road To Value-Based Payment: The Case Of Transcatheter Aortic Valve Replacement.”
    *Health Affairs Blog*, July 26, 2018.
267. Goldman D, Trish E. “Walmart and CVS have 15,000 combined stores. Why are both trying to buy health insurance companies?”
268. Jena A, Goldman D. “Here’s how we can increase the supply of organs and keep people off of the waiting list.”
269. Goldman D and Lakdawalla D. “Opinion: This is what’s at stake if U.S. drug prices fall — and Europeans don’t pay more.”
270. Sood N, Goldman D, Van Nuys K. “Follow the money to understand how drug profits flow.”
272. Goldman D. “Why Bernie Sanders’s plan for universal health care is only half right.”
274. Howard P, Goldman D. “This is how Congress could craft a bipartisan health-care bill.”
275. Goldman D, Lakdawalla D. “Take Me Out to the Pill Game.”
277. Goldman D, Jena A. “Value-based drug pricing makes sense, but is difficult to pull off.”
    *STAT*, June 8, 2017.
278. Hagopian K, Goldman D. “How To Insure Everyone At A Reasonable Cost.”
279. Schaeffer L, Goldman D. “California provides model to replace the Affordable Care Act.”
280. Goldman D, Lakdawalla D. “Why academics consulting with industry on health care may be an idea whose time has come.” *The Conversation*, December 21, 2016.


DISSERTATION COMMITTEES

Laura Henkhaus*
Title: Health care use, access, and economic welfare of adults with histories of childhood sexual abuse
Year: 2019
Position: https://www.linkedin.com/in/laurahenkhaus/

Eunhae Shin
Title: Essays in Health Economics and Provider Behavior
Year: 2019
Position: https://sites.google.com/view/eunhae-shin/home

Wei-Han (Wendy) Cheng
Title: The Value of PCSK9 inhibitors in the U.S. Healthcare System: Reducing the Burden of Cardiovascular Diseases and Filling the Gap of Low Adherence in Statins
Year: 2018
Position: https://www.linkedin.com/in/wei-han-wendy-cheng-a8053834/

Jakub Hlavka
Title: Three Essays in Health Economics Towards Alternative Payment Models for High-Value, High-Cost Medical Treatments
Year: 2018
Position: https://www.linkedin.com/in/jakubhlavka/

Zhiwen (Richard) Xie
Title: Three Essays on Health Economics
Year: 2018
Position: https://www.linkedin.com/in/richard-zhiwen-xie-52598522/

Amulya Yadav
Title: Artificial Intelligence for Low-Resource Communities: Influence Maximization in an Uncertain World
Year: 2018
Position: https://www.linkedin.com/in/amulyayadav/

Wei Xie*
Title: Panel Data Forecasting and Application to Epidemic Disease
Year: 2016
Position: https://www.linkedin.com/in/wei-xie-961a2223/

Sarah Axeen*
Title: Essays in Opioid Use and Abuse
Year: 2015
Position: https://www.linkedin.com/in/sarah-axeen-1553777/

Lauren Scarpati
Title: Essays in Health Economics: Evidence from Medicare
Year: 2015
Position: https://www.linkedin.com/in/lauren-scarpati-02641711/